Abstract
The prevalence of malignancy in patients undergoing lower extremity revascularization is rare at present. However, this population could increase in the future as cancer treatments progress and patient longevity improves. Malignancy is known to create a hypercoagulable or prothrombotic state owing to the ability of tumor cells to activate the coagulation system. We conducted an observational study using the 2011 to 2017 National Surgical Quality Improvement Program (NSQIP) data to evaluate the incidence of thrombotic complications in patients with disseminated cancer undergoing lower extremity endovascular revascularization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
